Can MDMA-AT Be Saved? Part II

"All MDMA Therapists Should Take MDMA," a Critique.

Welcome to The Frontier Psychiatrists. This article is Part II of a series on MDMA-AT. This is a flashback, now more potent than ever, to a prior article. In this article, I argued against the stance of Rick Doblin, the founder of MAPS and its associated drug company, MAPS PBC, rechristened Lykos Therapeutics, PBC. The data coming to the fore from the FDA Advisory Committee hearing is worrying. An idea that I was willing to write off as “kooky” and “not in keeping with the culture of medicine previously…seems a bit more sus now.

The first part is worth a read, here.

An overview of the FDA clinical trials process is here.

I will open this article with a comment from the FDA’s Open Comment period:

While one may argue the legitimacy of psychedelic spiritual beliefs on their own merits, how do we trust data when a company not only has financial conflicts of interest but open spiritual and religious conflicts of interest?

And like the worst of religions, including my own, what happens whe…